Brief: Tenaya Therapeutics Reports First Quarter 2023 Financial Results And Provides Business Update
10/05/2023 22:54
Tenaya Therapeutics Inc TNYA.O :
* TENAYA THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS
AND PROVIDES BUSINESS UPDATE
* TENAYA THERAPEUTICS INC - TN-201 RECEIVED FAST TRACK
DESIGNATION
FROM FDA
* TENAYA THERAPEUTICS INC - DOSING COMPLETE IN PHASE 1
CLINICAL
TRIAL OF TN-301; DATA EXPECTED IN SECOND HALF 2023
* TENAYA THERAPEUTICS INC - AS OF MARCH 31, 2023, CASH, CASH
EQUIVALENTS AND INVESTMENTS IN MARKETABLE SECURITIES WERE $173.6
MILLION
* TENAYA THERAPEUTICS - SEES CURRENT CASH, CASH EQUIVALENTS
&
INVESTMENTS IN MARKETABLE SECURITIES WILL BE SUFFICIENT TO FUND
CO INTO H1 OF 2025
Source text for Eikon: ID:nGNX6XklR5
Further company coverage: TNYA.O
Recent news on Tenaya Therapeutics
See all newsTenaya Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tenaya Therapeutics Q2 net loss widens on impairment charge
Brief: Tenaya Therapeutics Q2 Net Income USD -43.393 Million
Brief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401